Combination creates expanded scientific and geographic footprint to meet growing client demand for biospecimens

New Castle, DE — January 6, 2026 — ABS Bio, Inc., a leader in biospecimen sourcing, cell culture services and biorepository solutions for the global pharmaceutical and biotechnology industry, today announced the acquisition of Cureline, Inc., a South San Francisco, California-based provider of specimen procurement and histology services.

The combined entity creates an expanded, complementary service offering with nearly 300 clinical collection sites around the world. Together, the organizations will deliver broader, faster services to biopharma discovery and diagnostics clients.

“As we continue to expand ABS Bio’s capabilities, Cureline is the perfect strategic fit. Their team, services, and location align seamlessly with our mission and complement our existing strengths. We’re excited to welcome them aboard to deliver an enhanced service offering to our mutual clients,” commented ABS Bio CEO Ehab Alramahy. “Uniting ABS Bio and Cureline positions us to meet more client needs, deliver faster results, and meaningfully elevate the productivity of the research we support.”

Cureline Founder & CEO, Olga Potapova, Ph.D., added, “We are excited to join forces with ABS Bio. Their client-focused, science-first culture makes them an ideal fit for Cureline, our customers and research partners. We are confident that, together, we will bring a robust service offering that will delight our current and future clients.”

Since 1990, ABS Bio has provided nearly all of the world’s largest pharmaceutical companies with mission critical biomaterial services. In 2024, ABS Bio was acquired by 3 Boomerang Capital, a leading healthcare-focused private equity firm. Cureline, founded in 2003 is privately held. Acquisition terms were not disclosed.

About ABS Bio

Founded in 1990, ABS Bio has made research and discovery faster, easier, and more reliable for pharmaceutical and biotech developers. With a suite of custom services—including biospecimen sourcing, cell culture, and integrated biostorage—ABS Bio enables research teams to focus on core objectives while ensuring mission-critical functions are fulfilled with precision and quality. Based in New Castle, DE, ABS Bio is distinguished by consistently high satisfaction ratings from clients ranging from large pharma to emerging biotech. For more information, visit ABSBio.com.

About Cureline

Cureline is a global translational and precision medicine CRO (contract research organization) that provides biobanking and laboratory services for drug research and development, focusing on drug R&D and diagnostic development. Founded in 2003, the company’s services include acquiring and managing human biospecimens, performing translational histopathology and digital pathology, and conducting biomarker discovery and validation for clients in the biopharmaceutical industry and academia.

About 3 Boomerang Capital

3 Boomerang Capital is a lower middle market healthcare private equity firm committed to fostering creative investment partnerships with healthcare entrepreneurs across North America and Western Europe. 3BC’s areas of investment focus span four key healthcare sectors: Biopharma outsourcing, medical device and diagnostic manufacturing, information technology and tech-enabled services, and alternate site care. The firm specializes in backing founder-led businesses, providing the guidance and resources needed for successful growth and innovation in the healthcare market. By strategically concentrating on four core areas, 3 Boomerang Capital is well-equipped to deliver on its mission of empowering healthcare entrepreneurs and propelling healthcare businesses to new heights. The firm is currently investing out of its flagship fund, 3 Boomerang Capital I, LP, a $376 million investment vehicle. For more information, visit 3boomerang.com.

3 Boomerang Capital’s Portfolio Company Taps Accomplished Life Sciences Leader to Drive Next Phase of Growth, Further Strengthening Research & Discovery for Biotech & Pharma Developers

The original announcement can be viewed on PR NEWSWIRE.

NEW CASTLE, Del. and GREENWICH, Conn., July 9, 2025 — ABS Bio, Inc., (“ABS Bio” or “the Company”), a 3 Boomerang Capital (“3 Boomerang” or “3BC”) portfolio company and a leader in biospecimen sourcing, cell culture services, and biorepository solutions for the global pharmaceutical and biotechnology industry, today announced the appointment of Ehab Alramahy as President and Chief Executive Officer. Company founder Charles Saller, Ph.D., will step down from day-to-day leadership but continue serving on the Board of Directors.

Mr. Alramahy is a seasoned executive with a strong track record of driving commercial growth, building high-performing teams, and leading complex life science businesses across North America and Europe. He brings a powerful mix of scientific insight and strategic leadership, having previously led global divisions at BioIVT, Biosynth Group, and Bachem Group. His blend of hands-on technical experience and executive leadership uniquely positions him to guide ABS Bio’s next phase of growth.

“ABS Bio and 3 Boomerang Capital are thrilled to welcome Ehab Alramahy to this important role,” said John Chickosky, Executive Chairman of ABS Bio. “In our search for a successor, we prioritized deep domain expertise and a leadership style that reflects ABS Bio’s client-first culture. Ehab brings both to the table, and we are confident he will earn the trust of our team and our clients from day one.”

“I am honored to lead ABS Bio and excited to work alongside John, the Board, and the talented team to drive the Company forward,” said Ehab Alramahy, President and CEO of ABS Bio. “I am especially grateful to Charlie Saller for building such an exceptional organization and for remaining on the board to share his experience and counsel. ABS Bio has built a reputation for reliability and scientific excellence, and I look forward to expanding our impact across the biopharma industry.”

“ABS Bio has earned its place as a trusted partner to nearly all major pharma companies,” said Charles Saller. “Ehab’s experience, energy, and deep understanding of the scientific capabilities that make ABS Bio unique give me great confidence in the Company’s future.”

New Castle, DE —May 13, 2025 — ABS Bio, Inc., a leader in biospecimen sourcing, cell culture services and biorepository services for the global pharmaceutical and biotechnology industry, today announced the appointment of two accomplished industry leaders, Martin LeBlanc and Greg Swanberg, to its Board of Directors.

Other board members include executive chair John Chickosky, and directors Charles Saller, Ph.D. (ABS Bio founder and CEO), Adam Dolder (3 Boomerang Capital) and Logan Stinson (3 Boomerang Capital).

“We are pleased to welcome Martin and Greg to the ABS Bio Board,” said John Chickosky, executive chairman of ABS Bio. “They both bring deep experience in laboratory services for the global pharma and biopharmaceutical industry that will be invaluable to ABS as we grow our business and pursue our mission to power the discovery of new drugs and diagnostics.”

MARTIN LEBLANC
Martin is co-founder and was named Vice-Chairman of CellCarta Biosciences in 2023 after having served as CEO from 2007 to 2023 and COO from 2000 to 2007. Formerly known as Caprion Biosciences and headquartered in Montreal, Canada, CellCarta is a leading global provider of specialized precision medicine laboratory services to the biopharmaceutical industry. CellCarta operates globally with over 1000 employees in its 9 facilities located in Canada, the United States, Belgium, Australia and China. Under Martin’s leadership the company sustained strong organic revenue and profitability growth, concluded 10 company mergers and acquisitions, and has been managed under the successive ownership of 4 leading healthcare private equity firms: Great Point Partners LLP (2007-12), Chicago Growth Partners LLP (2012-16), GHO Capital (2016-19), and Arsenal Capital Partners (2019-present). He serves as chairman of the board of directors of Icentia, and Saguaro Biosciences as well as a member of the board of directors of Sygnature Discovery, IXCells Biotechnologies, ABS and Montreal In-Vivo. Martin earned his bachelor’s degree in Economics from the University of Moncton prior to completing an M.A. in Economics and Politics at Oxford University as a Rhodes Scholar.

GREG SWANBERG
Greg is currently CEO of Core Biosample Solutions and Founder and Chairman of Core UCO Systems. He was previously CEO of BioStorage Technologies (now Azenta). He has extensive operational and leadership experience of over 40 years in executive roles. His focus has centered on the outsourcing of critical technical operations for highly regulated industries such as Pharma/Bio research and manufacturing facilities, hospitals, data centers and nuclear power and weapons facilities. His involvement has ranged from serving as a major buyer of such services to consulting and advising pharma and bio companies in the development of outsourcing documentation and leading competitive bidding processes for corporations acquiring these services. For the last 15 years, his work has specifically centered on life science centered biorepository and associated sample management related services. Prior to joining the ABS Board, Greg has been closely engaged with ABS leadership in a variety of advisory roles including serving as a member of the company’s Industry Advisory Board.

New Castle, DE —April 29, 2025 —ABS Bio is pleased to welcome Libu Mathew, CPA as Chief Financial Officer (CFO).

Libu joins ABS from NJ Bio where he also served as CFO during a period that saw the company’s revenue grow by more than 2000%. NJ Bio is a leading Contract Research Organization (CRO)/ Contract Development and Manufacturing Organization (CDMO) headquartered in Princeton, NJ, with locations in Bristol, PA and Mumbai, India. Prior to NJ Bio, Libu held Financial Controller positions at Cello Health and Abzena.

“As ABS Bio is expanding on multiple fronts, Libu is playing an important role in strengthening our executive team. His efforts to date have already made significant impacts on our financial operations, systems and controls, and his leadership is helping make the entire organization more efficient and productive,” commented ABS Bio Founder & CEO, Charlie Saller, Ph.D.

Libu earned his Bachelors in Business Administration, Accounting at Drexel University in Philadelphia and is a Certified Public Accountant (CPA).

New Castle, DE —March 26, 2025 — ABS Bio, Inc., a leader in biospecimen sourcing, cell culture services and biorepository services for the global pharmaceutical and biotechnology industry, today announced that its Biorepository Operations have been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP) based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs. The CAP accreditation builds on ABS Bio’s 35 year track-record in biorepository services, including the handling, storage, and documentation of specimens. The accreditation covers both pre-clinical and clinical research specimens.

“For 35 years, ABS Bio has excelled at the processing, transport and storage of critical specimens. Our quality and reputation for protecting our clients’ critical assets has been a key driver of our success.”

Recognized for rigorous and robust standards, CAP accreditation elevates quality and mitigates risk, an important way that laboratories can contribute to improved client and patient outcomes. CAP is considered to be the most rigorous choice for lab accreditation.

“The College of American Pathologists is the gold standard for lab accreditation, and we are proud that our team earned their approval,” said Charles Saller, Ph.D., Founder & CEO of ABS Bio. “For 35 years, ABS Bio has excelled at the processing, transport and storage of critical specimens. Our quality and reputation for protecting our clients’ critical assets has been a key driver of our success. We believe adding CAP accreditation further cements our position as a partner that world-class clients can rely upon.”

“ABS Bio demonstrates leadership, innovation, and a passionate commitment to standards of excellence while providing the highest quality services, ultimately for patients,” said Richard M. Scanlan, MD, FCAP, chair of the CAP’s Council on Accreditation. “The CAP congratulates ABS Bio on its recent CAP Accreditation.”

During the CAP accreditation process, designed to ensure the highest standard of care, inspectors examine the laboratory’s records and quality control of procedures. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management. These reviews help verify activities and reflect the most recent best practices. Built on a foundation of pathologist expertise, the College of American Pathologists (CAP) partners with laboratories worldwide to elevate the quality of laboratory medicine with best-in-class solutions designed to drive operational excellence, achieve diagnostic confidence, and ensure the best patient care.

About the College of American Pathologists

As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide.

New Castle, DE —February 25, 2025  — ABS Bio is excited to return to San Diego for the 32nd International Precision Med Tri-Con Conference.

DETAILS: March 11-13 | San Diego | Booth 14

Our team will be ready to explore how our tailored solutions can energize your discovery efforts. We’ll also be sharing new developments in our core service areas:

• Human Biospecimens
• Integrated Biostorage Services
• Cell Culture Services

We invite you to learn why leading biopharma companies rely on ABS Bio to help make their research faster, easier, and more reliable!